Eli Lilly will remove four insulin drugs with low or falling sales from
the U.S. market, including its remaining animal-based insulins.
Biosynthetic insulins began replacing animal insulins in 1983. Two
percent of the 3.5 million insulin users in the U.S. depend on these
products and will have until the end of the year to find replacements.
The discontinued products make up a small percentage of the company's
total insulin sales of more than $2 billion a year.

Related Summaries